Gastric cancer molecular classification based on immunohistochemistry and in‐situ hybridisation and mortality
Histopathology · 2024-08 · 85 (2) · 327-337
DOI: 10.1111/his.15207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, online erschienen am 07.05.2024. Verfasst von Maarit Eskuri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer and Translational Medicine Research Unit, Medical Research Center, University of Oulu, Oulu University Hospital, Oulu, Finland. Hauptthemen laut MEDLINE: Stomach Neoplasms, Immunohistochemistry, In Situ Hybridization. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Finnish Medical Foundation, Maud Kuistila Memorial Foundation, Orion Research Foundation.
Abstract (Originalsprache)
Background and aims Gastric cancers (GC) are divided into subtypes based on molecular profile: Epstein–Barr virus (EBV)‐positive, microsatellite instability (MSI), chromosomal instability (CIN) and genomically stable (GS) tumours. The prognostic impact of this classification is unclear. The aim was to evaluate whether the molecular subtypes determined using in‐situ hybridisation (ISH) and immunohistochemistry (IHC) are associated with clinicopathological parameters and prognosis. Methods and results The study included 503 GC patients. Based on ISH (EBV) and IHC (MSI and TP53), tumours were divided into EBV‐positive, MSI, CIN (EBVneg/MSS/TP53aberrant) and GS (EBVneg/MSS/TP53wild‐type) subgroups. Survival analyses with intestinal‐ and diffuse‐type tumours were examined separately. EBV‐positive tumours associated with male sex. Both EBV‐positive and MSI tumours associated with intestinal type. CIN tumours associated with intestinal‐type and positive lymph node status. GS tumours associated with diffuse‐type and negative lymph node status. In the total cohort, no significant differences in the 5‐year survival were observed. In intestinal tumours, the 5‐year survival was better in EBV‐positive tumours compared with GS tumours [hazard ratio (HR) = 0.57, 95% confidence interval (CI) = 0.33–0.99]. In diffuse tumours, the 5‐year survival was worse in CIN tumours compared with GS tumours (HR = 1.57, 95% CI = 1.14–2.18). In radically resected diffuse tumours, the 5‐year survival was worse in MSI tumours compared with GS tumours (HR = 3.26, 95% CI = 1.20–8.82). Conclusions The molecular classification is associated with histological type but not prognosis in GC. As the prognostic effects of molecular subtypes in intestinal‐ and diffuse‐type cancers may differ, combining histological and molecular information is recommended for future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer and Translational Medicine Research Unit, Medical Research Center, University of Oulu, Oulu University Hospital, Oulu, Finland.
- Department of Pathology, University of Turku, Turku University Hospital, Turku, Finland.
- Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Maarit Eskuri
Förderung
- Finnish Medical Foundation
- Maud Kuistila Memorial Foundation
- Orion Research Foundation
- Thelma Mäkikyrö Foundation
- Mary and Georg C. Ehrnroot Foundation
- Päivikki and Sakari Sohlberg Foundation
- Finnish Cancer Foundation
- Sigrid Juselius Foundation
Zitieren
APA
Eskuri, M., Birkman, E. M., & Kauppila, J. H. (2024). Gastric cancer molecular classification based on immunohistochemistry and in‐situ hybridisation and mortality. Histopathology, 85(2), 327-337. https://doi.org/10.1111/his.15207
Vancouver
Eskuri M, Birkman EM, Kauppila JH. Gastric cancer molecular classification based on immunohistochemistry and in‐situ hybridisation and mortality. Histopathology. 2024;85(2):327-337. doi:10.1111/his.15207
BibTeX
@article{Eskuri2024,
author = {Eskuri, Maarit and Birkman, Eva-Maria and Kauppila, Joonas H},
title = {Gastric cancer molecular classification based on immunohistochemistry and in‐situ hybridisation and mortality},
journal = {Histopathology},
year = {2024},
volume = {85},
number = {2},
pages = {327--337},
doi = {10.1111/his.15207}
}
EUVIMED